Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
Date: February 21, 2022 Issue #: 1644 Summary: Odevixibat (Bylvay – Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic cholestasis (PFIC). It is the first drug to be approved in the US for this indication.